Focused On-demand Library for Signal transducer and activator of transcription 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14765

UPID:

STAT4_HUMAN

Alternative names:

Alternative UPACC:

Q14765; Q96NZ6

Background:

Signal transducer and activator of transcription 4 (STAT4) is a pivotal transcriptional regulator predominantly expressed in hematopoietic cells. It orchestrates cellular growth, differentiation, and immune responses. STAT4 is instrumental in T-helper 1 cell differentiation and interferon-gamma production, contributing to immune system precision. Its activation involves tyrosine phosphorylation upon IL12 or IFN-gamma stimulation, leading to nuclear translocation and gene transcription initiation.

Therapeutic significance:

STAT4's involvement in systemic lupus erythematosus and rheumatoid arthritis underscores its therapeutic potential. Given its critical role in immune response modulation and disease pathogenesis, targeting STAT4 could offer novel treatment avenues for these autoimmune conditions. Understanding STAT4's mechanisms opens doors to innovative therapeutic strategies, potentially transforming patient outcomes in autoimmune diseases.